Skip to Content
Authors Cooper M, Salvadori M, Budde K, Oppenheimer F, Sollinger H, Zeier M
Author Profile(s)
Journal Transplant Rev (Orlando) Volume: 26 Issue: 4 Pages: 233-40
Publish Date 2012 Oct
PubMed ID 22863029

Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization. Copyright © 2017 The Board of Regents of the University of Wisconsin System